Mastectomy
Methodology & AI Transparency ⓘ
Mastectomy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is a mastectomy? A mastectomy is surgery to remove part or all of the breast.
- 2 Real-world patient consensus: Mapped to Cancer, Oncology & Supportive Care under ICD-10-CM C64.9 for Mastectomy clinical workups.
- 3 Typical cash cost range: Differential triage of Mastectomy (C64.9) utilizes radiation) paired with in Mastectomy (C64.9: proactive supportive symptom).
- 4 Top reported side effects / signs: Objective lab/clinical target for Mastectomy: Complete Blood Count in Mastectomy (C64.9: (ANC, Hemoglobin, Platelets)) (Safe hematologic reserve (C64.9)) and Comprehensive Metabolic & in Mastectomy (C64.9: Organ Function Panel).
Ask our AI Specialists anything about Mastectomy
What Is Mastectomy?
What is a mastectomy? A mastectomy is surgery to remove part or all of the breast. It's usually done to treat breast cancer by removing the cancer. A mastectomy may be the first treatment option for some types of breast cancer or done after chemotherapy for other types. If you are at a very high risk for breast cancer, sometimes a mastectomy may be done to reduce your risk. What are the different types of mastectomies? There are different types of mastectomies. Each differs in the amount of breast tissue and lymph nodes that are removed. Some types of breast surgery remove the breast skin and the nipple.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Mastectomy (ICD-10 C64.9) is driven by tumor-suppressor loss enabling in Mastectomy (C64.9: clonal proliferation); Cross-referenced with NIH MeSH (Mastectomy), specialists in Cancer, Oncology & Supportive Care monitor Comprehensive Metabolic & in Mastectomy (C64.9: Organ Function Panel) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Mastectomy (C64.9): unintended weight loss [Mastectomy C64.9]
- • Secondary Mastectomy clinical sign: unexplained bleeding, chronic in Mastectomy (C64.9: hoarseness/cough, or progressive)
- • Symptom flares in Mastectomy correlating with Complete Blood Count in Mastectomy (C64.9: (ANC, Hemoglobin, Platelets)) deviation outside Safe hematologic reserve (C64.9)
- • Functional cancer & oncology impact requiring radiation) paired with in Mastectomy (C64.9: proactive supportive symptom) evaluation (C64.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Mastectomy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C64.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Mastectomy (C64.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C64.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Mastectomy (C64.9: Organ Function Panel) | Preserved renal/hepatic clearance (C64.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Mastectomy (C64.9: Genomic Staging) | Guideline-concordant surveillance (C64.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Mastectomy
Treatment selection for Mastectomy depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mastectomy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Beyond the first cut: Impact of repeat surgery versus boost on breast: What a 1,919-Participant Study Found A tumour-bed boost was associated with a higher risk of breast induration compared to RS, with no difference in cosmetic outcome. Breast (Edinburgh, Scotland) • 2025-12-15 • Phase III Randomized Trial | N = 1,919 | 90/100 | PMID 41043314 ↗ |
| New Insights on Segmentectomy Versus Lobectomy in NSCLC With Pathologically Invasive Features: A: What a 1,106-Participant Study Found Segmentectomy demonstrated better OS compared with lobectomy even for NSCLC harboring pathologically invasive features. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2026-10-15 • Phase III Randomized Trial | N = 1,106 | 90/100 | PMID 42119729 ↗ |
| New Insights on Breast-Conserving Surgery with or without Irradiation in Early Breast: What a 1,326-Participant Study Found Omission of radiotherapy was associated with an increased incidence of local recurrence but had no detrimental effect on distant recurrence as the first event or overall survival among women 65 years of age or older with... The New England journal of medicine • 2023-02-16 • Phase III Randomized Trial | N = 1,326 | 90/100 | PMID 36791159 ↗ |
| Can This Approach Help? Inside the Latest Research on Eltrombopag during induction chemotherapy in older patients with newly diagnosed This study failed to demonstrate a survival advantage after eltrombopag addition, at variance with previous reports, but shows that initiating eltrombopag after chemotherapy washout is feasible and safe, and resulted in a... Cancer • 2026-11-01 • Randomized Controlled Trial | N = 110 | 88/100 | PMID 42963911 ↗ |
| New Insights on HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-Risk Patients: What a 941-Participant Study Found Dysphagia was less with the 1-week RT schedule as compared to the 2-week schedule. International journal of radiation oncology, biology, physics • 2026-01-01 • Phase III Randomized Trial | N = 941 | 87/100 | PMID 40780546 ↗ |
Mastectomy Patient Community & “People Like Me” Threads
Filter Mastectomy community threads and patient logs by age, biological sex, dosage, and treatment duration.